{"version": "https://jsonfeed.org/version/1.1", "title": "Sharemaestro Newsreel: United States Health Information Services news", "home_page_url": "https://sharemaestro.com/newsreel/us/healthcare/health-information-services/", "feed_url": "https://sharemaestro.com/newsreel/us/healthcare/health-information-services/feed.json", "description": "Latest Health Information Services company headlines from United States, newest first, with source links and direct routes to company research and sentiment.", "language": "en", "items": [{"id": "source:16b3d68e8ab2dff3040c909a484f7ce822135a1fba08e48f3f45d97598dc9959", "url": "https://news.google.com/rss/articles/CBMipgFBVV95cUxPWFQzVzNyLVRTMHNNMElvcXJJN01HWU45c18yalNla0JCZ0M4TGlzdjdQV21ncGpnUWZ4dHRyWGs4bnN6Q1dWa09ua25wcXNoLTNvTnhXWE0teVlOcmIySkhqdnNaNjZId3Yzb0xLQkU5akE3RUdneDdNak90b3U3LWMwMUxSSElKTTBPaWNSUGJLUGVyOWVBNGxGeVNqbjBWbUlqYzZ3?oc=5", "external_url": "https://news.google.com/rss/articles/CBMipgFBVV95cUxPWFQzVzNyLVRTMHNNMElvcXJJN01HWU45c18yalNla0JCZ0M4TGlzdjdQV21ncGpnUWZ4dHRyWGs4bnN6Q1dWa09ua25wcXNoLTNvTnhXWE0teVlOcmIySkhqdnNaNjZId3Yzb0xLQkU5akE3RUdneDdNak90b3U3LWMwMUxSSElKTTBPaWNSUGJLUGVyOWVBNGxGeVNqbjBWbUlqYzZ3?oc=5", "title": "Reflecting On Healthcare Technology Stocks\u2019 Q2 Earnings: GoodRx (NASDAQ:GDRX)", "content_text": "Reflecting On Healthcare Technology Stocks\u2019 Q2 Earnings: GoodRx (NASDAQ:GDRX)", "date_published": "2026-08-14T15:49:00+00:00", "authors": [{"name": "Market source"}], "tags": ["Earnings", "GDRX"], "_sharemaestro": {"country": "United States", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "GDRX", "name": "Goodrx Holdings\u00a0Inc", "sentiment_url": "https://sharemaestro.com/sentiment/78134086-d01e-488f-b9bd-1f2f022b49f2/"}]}}, {"id": "source:2792d6ef5c2e50e7e11472a10c57c26410263e5225b8879409701e89fad83d6e", "url": "https://finance.yahoo.com/healthcare/articles/reasons-hold-hinge-health-stock-153600785.html", "external_url": "https://finance.yahoo.com/healthcare/articles/reasons-hold-hinge-health-stock-153600785.html", "title": "Reasons to Hold Hinge Health Stock in Your Portfolio for Now", "content_text": "Hinge Health HNGE is well-positioned for sustained growth, driven by robust revenue growth, expanding opportunities in Migraine and gastrointestinal (GI) care and a scalable AI-powered MSK platform. The raised 2026 outlook, broader enterprise reach and growing sales pipeline further support the growth outlook. However, continued investments and Cylinder Health integration could weigh on margin expansion. This Zacks Rank #3 (Hold) company's shares have surged 88.2% in the year-to-date period compared with the 2.4% growth of the industry. The S&P 500 Composite has increased 12.8% during the said", "date_published": "2026-08-14T15:36:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "HNGE"], "_sharemaestro": {"country": "United States", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "HNGE", "name": "Hinge Health, Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/5e193ce6-020e-42a6-9585-2f3b4a202c69/"}]}}, {"id": "source:5632885834590471f28450629974a7d7c3769a37aafbb000861a22b295733b47", "url": "https://news.google.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?oc=5", "external_url": "https://news.google.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?oc=5", "title": "Is Privia Health Group (PRVA) A Bargain As Earnings Growth And Guidance Improve?", "content_text": "Is Privia Health Group (PRVA) A Bargain As Earnings Growth And Guidance Improve?", "date_published": "2026-08-14T14:34:09+00:00", "authors": [{"name": "simplywall.st"}], "tags": ["Earnings", "PRVA"], "_sharemaestro": {"country": "United States", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "PRVA", "name": "Privia Health Group Inc", "sentiment_url": "https://sharemaestro.com/sentiment/604c2b29-650d-4f2d-9955-bca5ec7509ed/"}]}}, {"id": "source:052293b78b6a6ed5a0fdcfc0809f95f038043d606619a8cbe5d7ea685317d19f", "url": "https://news.google.com/rss/articles/CBMi2AFBVV95cUxOT1BScEZ6Z3BaZlhDNnQyMlgxV0N3WktpR0xGSkI0cFZOeG1iVmJhcGpHTFZrb0dsQ1oxU0h3ak5hNDA1TXdoMzZpNnhPVHlIMnpfM2xfNElZdXJ5cFpaNUZXS2V0WVNjNnp4c1B3Y1NqTW5mTlYtU0p1MS1Db25HQVJ1RF9jVmpTQ281bDZpSUtFMlplTk9EbHV3V0dLVWN0a3dzVkc3VHB1TGJpUzhYcHkyeHJuelltZkhNQmNaNVRET3paLWZ2N0lmX1hnLTBVS19LSWYweW4?oc=5", "external_url": "https://news.google.com/rss/articles/CBMi2AFBVV95cUxOT1BScEZ6Z3BaZlhDNnQyMlgxV0N3WktpR0xGSkI0cFZOeG1iVmJhcGpHTFZrb0dsQ1oxU0h3ak5hNDA1TXdoMzZpNnhPVHlIMnpfM2xfNElZdXJ5cFpaNUZXS2V0WVNjNnp4c1B3Y1NqTW5mTlYtU0p1MS1Db25HQVJ1RF9jVmpTQ281bDZpSUtFMlplTk9EbHV3V0dLVWN0a3dzVkc3VHB1TGJpUzhYcHkyeHJuelltZkhNQmNaNVRET3paLWZ2N0lmX1hnLTBVS19LSWYweW4?oc=5", "title": "Dimensional Fund Advisors LP Has $1.85 Million Stock Holdings in Tempus AI, Inc. $TEM", "content_text": "Dimensional Fund Advisors LP Has $1.85 Million Stock Holdings in Tempus AI, Inc. $TEM", "date_published": "2026-08-14T08:10:59+00:00", "authors": [{"name": "MarketBeat"}], "tags": ["Market update", "TEM"], "_sharemaestro": {"country": "United States", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "TEM", "name": "Tempus AI, Inc. Class A Common Stock", "sentiment_url": "https://sharemaestro.com/sentiment/ba6f7609-8a92-49d6-a7a9-38348863348c/"}]}}, {"id": "source:a4b892c5ecdb6b6542608253ea5bd45a6496e0d7084753b79f93de9e0dc98975", "url": "https://www.tradingview.com/news/tradingview:5cfac66474d1b:0-schrodinger-inc-stock-12-month-price-target-raised-to-21-83-implies-18-upside", "external_url": "https://www.tradingview.com/news/tradingview:5cfac66474d1b:0-schrodinger-inc-stock-12-month-price-target-raised-to-21-83-implies-18-upside", "title": "Schrodinger, Inc. Stock 12\u2011Month Price Target Raised to $21.83, Implies 18% Upside", "content_text": "Schrodinger, Inc.'s average stock price target has increased to $21.83, up from $20.57, according to six analysts. This new target suggests an 18% potential upside from the August 13 closing price, with individual forecasts ranging from $17 to $30 per share. The consensus rating for the stock remains a \"Buy,\" with five out of six analysts recommending a Buy and one a Hold.", "date_published": "2026-08-14T07:12:47+00:00", "authors": [{"name": "TradingView"}], "tags": ["Analyst action", "SDGR"], "_sharemaestro": {"country": "United States", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "SDGR", "name": "Schrodinger Inc", "sentiment_url": "https://sharemaestro.com/sentiment/f14a9dba-9044-422a-96ad-cab8dfc3abd7/"}]}}, {"id": "source:40c9acda3ddb8a754e26a8d6367fcc5a6f807e5b369bac71d9fe49165e8930b6", "url": "https://seekingalpha.com/news/4633026-heartflow-projects-246m-250m-2026-revenue-as-plaque-outlook-rises-to-29m-31m?amp%3Butm_medium=referral&amp%3Bfeed_item_type=news", "external_url": "https://seekingalpha.com/news/4633026-heartflow-projects-246m-250m-2026-revenue-as-plaque-outlook-rises-to-29m-31m?amp%3Butm_medium=referral&amp%3Bfeed_item_type=news", "title": "HeartFlow projects $246M-$250M 2026 revenue as Plaque outlook rises to $29M-$31M", "content_text": "Earnings Call Insights: HeartFlow (HTFL) Q2 2026 MANAGEMENT VIEW * \"Q2 is an outstanding quarter for HeartFlow and the momentum that we entered 2026 with is accelerating,\" said (President, CEO & Director John Farquhar). \"In the second quarter, revenue was $64.1 million, up 48% year-over-year, with U.S. revenue up 51%.\" * \"The strength of our second quarter performance gives us confidence to raise our full-year outlook again,\" said (President Farquhar). \"We're now expected to deliver total revenue of $246 million to $250 million, representing 40% to 42% year-over-year growth.\" He added, \"We're ", "date_published": "2026-08-14T04:39:08+00:00", "authors": [{"name": "seekingalpha.com"}], "tags": ["Earnings", "HTFL"], "_sharemaestro": {"country": "United States", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "HTFL", "name": "Heartflow, Inc. Common Stock", "sentiment_url": "https://sharemaestro.com/sentiment/96e61f2a-ac09-4d51-a8bb-a6e6d25a9b2c/"}]}}, {"id": "source:a1eedf57f01137be6a525293f98fe43ac40b4b76985c557185e19e5315838b3a", "url": "https://finance.yahoo.com/markets/stocks/articles/doximity-doubled-then-gave-most-233528723.html", "external_url": "https://finance.yahoo.com/markets/stocks/articles/doximity-doubled-then-gave-most-233528723.html", "title": "Doximity Doubled, Then Gave Most of It Back. Here\u2019s Why the Market Doesn\u2019t Trust the Rally", "content_text": "For a few hours on August 7, Doximity, Inc. (NYSE:DOCS) appeared to be the story of the earnings season. The medical-networking platform's stock more than doubled overnight following its fiscal first-quarter report, with CEO Jeffrey Tangney mentioning a metric that piqued traders' interest: the company's new AI Search product, he claimed on the results call, generates more than ten times what it costs to run. That's about as good as unit economics get. However, by the time the rush subsided, the stock had given back the majority of its gains. Shares began around $38.86 on the move, surged to a", "date_published": "2026-08-13T23:35:28+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "DOCS"], "_sharemaestro": {"country": "United States", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "DOCS", "name": "Doximity Inc", "sentiment_url": "https://sharemaestro.com/sentiment/c6ba857b-6a36-47f4-8ae1-3678efe8d188/"}]}}, {"id": "source:f9a54737e0b3a176ce08a9953e28ca86c3ea9878856131e3868fa35070894367", "url": "https://m.investing.com/news/insider-trading-news/waystar-ceo-matthew-hawkins-sells-206m-in-company-stock-93CH-4859541?ampMode=1", "external_url": "https://m.investing.com/news/insider-trading-news/waystar-ceo-matthew-hawkins-sells-206m-in-company-stock-93CH-4859541?ampMode=1", "title": "Waystar CEO Matthew Hawkins sells $2.06m in company stock", "content_text": "Waystar Holding Corp. CEO Matthew Hawkins sold approximately $2.06 million worth of company stock across two transactions in mid-August 2026, following the exercise of stock options. These sales were conducted under a Rule 10b5-1 trading plan. Despite the insider sales, Waystar reported strong Q2 2026 results with significant revenue and adjusted EBITDA growth, leading to raised full-year guidance and maintained \"Buy\" and \"Overweight\" ratings from analysts, though one adjusted its price target downward.", "date_published": "2026-08-13T23:09:59+00:00", "authors": [{"name": "Investing.com"}], "tags": ["Earnings", "WAY"], "_sharemaestro": {"country": "United States", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "WAY", "name": "Waystar Holding Corp. Common Stock", "sentiment_url": "https://sharemaestro.com/sentiment/e19b284a-7576-4888-9963-a3cde3594442/"}]}}, {"id": "source:320be82c9aabe0d78acb3f9bfac5981b6021934f7443b63a1e015870c1e0c55c", "url": "https://www.stocktitan.net/sec-filings/WAY/form-4-waystar-holding-corp-insider-trading-activity-f123edd22d7a.html", "external_url": "https://www.stocktitan.net/sec-filings/WAY/form-4-waystar-holding-corp-insider-trading-activity-f123edd22d7a.html", "title": "Waystar (WAY) CEO Hawkins exercises 82,500 options and sells shares under plan", "content_text": "Waystar Holding Corp. CEO Matthew J. Hawkins exercised 82,500 stock options at $4.14 per share and subsequently sold the same number of shares in open-market transactions for approximately $25.0358 and $25.0121 per share. These transactions were executed under a pre-arranged Rule 10b5-1(c) trading plan. Hawkins continues to hold significant vested options indirectly through grantor retained annuity trusts.", "date_published": "2026-08-13T22:09:59+00:00", "authors": [{"name": "Stock Titan"}], "tags": ["Earnings", "WAY"], "_sharemaestro": {"country": "United States", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "WAY", "name": "Waystar Holding Corp. Common Stock", "sentiment_url": "https://sharemaestro.com/sentiment/e19b284a-7576-4888-9963-a3cde3594442/"}]}}, {"id": "source:928823bcde70bb7367b7a01d4b7cf5f0da09d639dff31e4c00c60b5634135b1b", "url": "https://finance.yahoo.com/healthcare/articles/heartflow-htfl-reports-q2-loss-213502995.html", "external_url": "https://finance.yahoo.com/healthcare/articles/heartflow-htfl-reports-q2-loss-213502995.html", "title": "HeartFlow (HTFL) Reports Q2 Loss, Beats Revenue Estimates", "content_text": "HeartFlow (HTFL) came out with a quarterly loss of $0.07 per share versus the Zacks Consensus Estimate of a loss of $0.14. This compares to a loss of $1.46 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of +50.00%. A quarter ago, it was expected that this medical technology company would post a loss of $0.18 per share when it actually produced a loss of $0.16, delivering a surprise of +11.11%. Over the last four quarters, the company has surpassed consensus EPS estimates three times. HeartFlow, which belongs to th", "date_published": "2026-08-13T21:35:02+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "HTFL"], "_sharemaestro": {"country": "United States", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "HTFL", "name": "Heartflow, Inc. Common Stock", "sentiment_url": "https://sharemaestro.com/sentiment/96e61f2a-ac09-4d51-a8bb-a6e6d25a9b2c/"}]}}, {"id": "source:5f54df9b0bd4d9f4985c67c08d5cb6bb9181dfcdb661a1c30f70b970d3c0bfa6", "url": "https://finance.yahoo.com/healthcare/articles/gossamer-bio-goss-reports-q2-211502157.html", "external_url": "https://finance.yahoo.com/healthcare/articles/gossamer-bio-goss-reports-q2-211502157.html", "title": "Gossamer Bio (GOSS) Reports Q2 Loss, Tops Revenue Estimates", "content_text": "Gossamer Bio (GOSS) came out with a quarterly loss of $0.2 per share versus the Zacks Consensus Estimate of a loss of $0.1. This compares to a loss of $0.17 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of -100.00%. A quarter ago, it was expected that this biopharmaceutical company would post a loss of $0.17 per share when it actually produced a loss of $0.2, delivering a surprise of -17.65%. Over the last four quarters, the company has not been able to surpass consensus EPS estimates. Gossamer Bio, which belongs", "date_published": "2026-08-13T21:15:02+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "VEEV"], "_sharemaestro": {"country": "United States", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "VEEV", "name": "Veeva Systems Inc Class A", "sentiment_url": "https://sharemaestro.com/sentiment/60f17108-f228-452e-9be1-7f86c73f1769/"}]}}, {"id": "source:bb875ff743b693499f569f60566e5d24bf1a757f0ed36e6e733e7309a9350743", "url": "https://www.stocktitan.net/sec-filings/HTFL/schedule-13g-a-heartflow-inc-amended-passive-investment-disclosure-ea95e2e59706.html", "external_url": "https://www.stocktitan.net/sec-filings/HTFL/schedule-13g-a-heartflow-inc-amended-passive-investment-disclosure-ea95e2e59706.html", "title": "Wellington Management reports 9.12% Heartflow (HTFL) stake in Schedule 13G/A", "content_text": "Wellington Management Group LLP and its related entities have filed an amended Schedule 13G (Amendment No. 3) for Heartflow, Inc. (HTFL), reporting a beneficial ownership of 9.12% of the common stock, totaling 7,864,226 shares as of June 30, 2026. The filing indicates shared voting power over 7,531,447 shares and shared dispositive power over up to 7,864,226 shares. The shares are held on behalf of clients of Wellington-affiliated investment advisers, with Vanguard Health Care Fund being the only client reported to hold rights over more than five percent of the class.", "date_published": "2026-08-13T20:11:09+00:00", "authors": [{"name": "Stock Titan"}], "tags": ["Earnings", "HTFL"], "_sharemaestro": {"country": "United States", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "HTFL", "name": "Heartflow, Inc. Common Stock", "sentiment_url": "https://sharemaestro.com/sentiment/96e61f2a-ac09-4d51-a8bb-a6e6d25a9b2c/"}]}}, {"id": "source:da95badad2e72ef35c2aefcc15fd2d802fddd6376456918bcf3319fe57ace573", "url": "https://www.manilatimes.net/2026/08/14/tmt-newswire/globenewswire/heartflow-reports-second-quarter-2026-financial-results-and-raises-full-year-2026-guidance/2405264", "external_url": "https://www.manilatimes.net/2026/08/14/tmt-newswire/globenewswire/heartflow-reports-second-quarter-2026-financial-results-and-raises-full-year-2026-guidance/2405264", "title": "Heartflow Reports Second Quarter 2026 Financial Results and Raises Full Year 2026 Guidance", "content_text": "Heartflow, a leader in AI technology for diagnosing coronary artery disease, reported strong financial results for the second quarter of 2026, with total revenue increasing by 48% year-over-year to $64.1 million. The company also raised its full-year 2026 revenue guidance to between $246 million and $250 million, reflecting confidence in its AI technology platform and the growing adoption of its FFRCT and Plaque Analysis products. Heartflow emphasized improving operating leverage and record gross margins as indicators of its path towards long-term profitable growth.", "date_published": "2026-08-13T20:11:09+00:00", "authors": [{"name": "The Manila Times"}], "tags": ["Earnings", "HTFL"], "_sharemaestro": {"country": "United States", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "HTFL", "name": "Heartflow, Inc. Common Stock", "sentiment_url": "https://sharemaestro.com/sentiment/96e61f2a-ac09-4d51-a8bb-a6e6d25a9b2c/"}]}}, {"id": "source:651868931d6a2fedf33f5db452c26524d2d189447f95ad5b9ddcd730c529ae90", "url": "https://www.tradingview.com/news/tradingview:491c0809d8569:0-heartflow-posts-q2-2026-revenue-64-1m-raises-2026-revenue-outlook-to-246-250m", "external_url": "https://www.tradingview.com/news/tradingview:491c0809d8569:0-heartflow-posts-q2-2026-revenue-64-1m-raises-2026-revenue-outlook-to-246-250m", "title": "Heartflow posts Q2 2026 revenue $64.1M, raises 2026 revenue outlook to $246\u2013250M", "content_text": "Heartflow reported strong second-quarter 2026 results with total revenue of $64.1 million, a 48% year-over-year increase, and significantly narrowed its non-GAAP net operating loss. The company achieved a record gross margin of 83.0% and raised its full-year 2026 revenue guidance to $246 million\u2013$250 million. This growth was primarily driven by increased U.S. FFRCT and Plaque case volumes, with Plaque analysis emerging as a key second growth engine.", "date_published": "2026-08-13T20:11:09+00:00", "authors": [{"name": "TradingView"}], "tags": ["Earnings", "HTFL"], "_sharemaestro": {"country": "United States", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "HTFL", "name": "Heartflow, Inc. Common Stock", "sentiment_url": "https://sharemaestro.com/sentiment/96e61f2a-ac09-4d51-a8bb-a6e6d25a9b2c/"}]}}, {"id": "source:7890965cc2927c223eaf822876dd4a2e16aab54ac90085e97ad2f23d5443ac8f", "url": "https://m.investing.com/news/earnings/heartflow-soars-15-on-earnings-beat-raised-guidance-93CH-4859137?ampMode=1", "external_url": "https://m.investing.com/news/earnings/heartflow-soars-15-on-earnings-beat-raised-guidance-93CH-4859137?ampMode=1", "title": "Heartflow soars 15% on earnings beat, raised guidance", "content_text": "Heartflow Inc. (NASDAQ:HTFL) reported strong second-quarter results, exceeding analyst expectations with an adjusted loss per share of -$0.07 and revenue of $64.1 million. The company also raised its full-year 2026 revenue guidance to $246 million-$250 million, leading to a 15% surge in after-hours trading. Growth was primarily driven by increased U.S. case volume for its FFRCT and Plaque products, along with expanded adjusted gross margin due to higher volume and improved efficiency.", "date_published": "2026-08-13T20:11:09+00:00", "authors": [{"name": "Investing.com"}], "tags": ["Earnings", "HTFL"], "_sharemaestro": {"country": "United States", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "HTFL", "name": "Heartflow, Inc. Common Stock", "sentiment_url": "https://sharemaestro.com/sentiment/96e61f2a-ac09-4d51-a8bb-a6e6d25a9b2c/"}]}}, {"id": "source:4d4b005cc5543d033ea0257c63e482f9c3da19a3fd76a7683c14462dd1a57eaf", "url": "https://www.stocktitan.net/sec-filings/WAY/144-waystar-holding-corp-sec-filing-a74c1e771bf1.html", "external_url": "https://www.stocktitan.net/sec-filings/WAY/144-waystar-holding-corp-sec-filing-a74c1e771bf1.html", "title": "WAY (NASDAQ: WAY) insider plans sale of 51,360 shares after option exercises", "content_text": "An insider at Waystar Holding Corp. (NASDAQ: WAY) has filed a Form 144 indicating a planned sale of 51,360 common shares. This sale is scheduled for August 13, 2026, and follows option exercises for 7,882 and 43,478 shares on August 11, 2026, through Morgan Stanley Smith Barney LLC Executive Financial Services. The filing ensures transparency regarding the impending stock transaction on NASDAQ.", "date_published": "2026-08-13T20:10:00+00:00", "authors": [{"name": "Stock Titan"}], "tags": ["Market update", "WAY"], "_sharemaestro": {"country": "United States", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "WAY", "name": "Waystar Holding Corp. Common Stock", "sentiment_url": "https://sharemaestro.com/sentiment/e19b284a-7576-4888-9963-a3cde3594442/"}]}}, {"id": "source:00a779183c8bf91a522da2b18c529e60ac69159030eae6360ebb4b890eaf6624", "url": "https://finance.yahoo.com/markets/stocks/articles/truist-lifts-doximity-target-24-191954373.html", "external_url": "https://finance.yahoo.com/markets/stocks/articles/truist-lifts-doximity-target-24-191954373.html", "title": "Truist Lifts Doximity Target to $24 and Stays on Hold", "content_text": "This article first appeared on GuruFocus. Doximity (NYSE:DOCS), a digital platform for US medical professionals, rose 0.46% premarket after Truist Securities raised its price target to $24 from $19 and reiterated a Hold rating. The stock is already trading around that level. Truist now looks for revenue of $673 million in fiscal 2027 and $716 million in fiscal 2028, against prior estimates of $664 million and $695 million. Adjusted EBITDA went the other way in the near term, trimmed to $320 million for fiscal 2027 from $323 million, while fiscal 2028 nudged up to $347 million from $344 million", "date_published": "2026-08-13T19:19:54+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Analyst action", "DOCS"], "_sharemaestro": {"country": "United States", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "DOCS", "name": "Doximity Inc", "sentiment_url": "https://sharemaestro.com/sentiment/c6ba857b-6a36-47f4-8ae1-3678efe8d188/"}]}}, {"id": "source:17ecca8324863d69a5348bad30c00dcc5302ada566150b125b1644dcc57b7741", "url": "https://finance.yahoo.com/technology/ai/articles/fourteen-183031221.html", "external_url": "https://finance.yahoo.com/technology/ai/articles/fourteen-183031221.html", "title": "Privia Health\u2019s (PRVA) Guidance Keeps Rising, So Is The Stock Keeping Pace?", "content_text": "Privia Health (NASDAQ:PRVA) just turned in a quarter that checked every box management set for itself, and then raised the bar again for the rest of the year. On the company's August 6 earnings call, CEO Parth Mehrotra and CFO David Mountcastle laid out a business adding doctors, patients, and cash at a pace that has held for nine straight years. The question is whether the market is pricing in the streak continuing.HPE Price Target Raised to $28 as Corporate AI Spending Accelerates Bull Case: A Growth Engine Still Humming Privia's numbers move together. Implemented providers grew 10.1% year-o", "date_published": "2026-08-13T18:30:16+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Analyst action", "PRVA"], "_sharemaestro": {"country": "United States", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "PRVA", "name": "Privia Health Group Inc", "sentiment_url": "https://sharemaestro.com/sentiment/604c2b29-650d-4f2d-9955-bca5ec7509ed/"}]}}, {"id": "source:f5e6316b182348d8122d9d6c345fe4bd93dde7a0388855866d67ba7d0e12de14", "url": "https://news.google.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?oc=5", "external_url": "https://news.google.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?oc=5", "title": "GoodRx (GDRX) Stock Trades At A Premium On Earnings Despite Weak Returns", "content_text": "GoodRx (GDRX) Stock Trades At A Premium On Earnings Despite Weak Returns", "date_published": "2026-08-13T18:27:59+00:00", "authors": [{"name": "simplywall.st"}], "tags": ["Earnings", "GDRX"], "_sharemaestro": {"country": "United States", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "GDRX", "name": "Goodrx Holdings\u00a0Inc", "sentiment_url": "https://sharemaestro.com/sentiment/78134086-d01e-488f-b9bd-1f2f022b49f2/"}]}}, {"id": "source:3d8c0ae750ef22bc967dbf0d2b1a0345a2197b98096291e08df7e20abcd0cf68", "url": "https://www.gurufocus.com/news/9031942/hcat-maintains-by-wells-fargo-price-target-lowered-to-150", "external_url": "https://www.gurufocus.com/news/9031942/hcat-maintains-by-wells-fargo-price-target-lowered-to-150", "title": "HCAT Maintains by Wells Fargo -- Price Target Lowered to $1.50", "content_text": "Wells Fargo has maintained an Equal-Weight rating for Health Catalyst (HCAT) but lowered its price target to $1.50 from $1.75, citing concerns over growth expectations in a challenging healthcare environment. Despite this, GuruFocus assesses HCAT as 57.3% undervalued with a GF Value\u2122 of $4.16 against a current price of $1.77, though its GF Score\u2122 of 52/100 points to challenges in profitability and financial strength. Investors are advised to proceed with caution due to ongoing losses and cash flow issues, despite the perceived undervaluation.", "date_published": "2026-08-13T14:40:56+00:00", "authors": [{"name": "GuruFocus"}], "tags": ["Analyst action", "HCAT"], "_sharemaestro": {"country": "United States", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "HCAT", "name": "Health Catalyst Inc", "sentiment_url": "https://sharemaestro.com/sentiment/d69fd9ea-c0d6-4784-9d56-601dd1a6f72d/"}]}}, {"id": "source:4c8f8d80dd29a6a1cc5b492ac02d246d749c73e2ae2ac9267649e7235f79dd0b", "url": "https://www.ktvb.com/article/syndication/associatedpress/heartflow-q2-earnings-snapshot/616-b36eac31-6440-4348-877b-78f8191c66a5", "external_url": "https://www.ktvb.com/article/syndication/associatedpress/heartflow-q2-earnings-snapshot/616-b36eac31-6440-4348-877b-78f8191c66a5", "title": "HeartFlow: Q2 Earnings Snapshot", "content_text": "HeartFlow Inc. (HTFL) reported a Q2 loss of $15.7 million, or 18 cents per share, which adjusted to 7 cents per share, beating analyst expectations. The medical technology company also surpassed revenue forecasts with $64.1 million for the period and projects full-year revenue between $246 million and $250 million. These results indicate a stronger financial performance than anticipated by Wall Street analysts.", "date_published": "2026-08-13T14:28:00+00:00", "authors": [{"name": "KTVB"}], "tags": ["Earnings", "HTFL"], "_sharemaestro": {"country": "United States", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "HTFL", "name": "Heartflow, Inc. Common Stock", "sentiment_url": "https://sharemaestro.com/sentiment/96e61f2a-ac09-4d51-a8bb-a6e6d25a9b2c/"}]}}, {"id": "source:e92fec65fbbf79de672d698f29567c4df32c948720326680a5b817d14430885e", "url": "https://finance.yahoo.com/markets/stocks/articles/1-small-cap-stock-solid-142100976.html", "external_url": "https://finance.yahoo.com/markets/stocks/articles/1-small-cap-stock-solid-142100976.html", "title": "1 Small-Cap Stock with Solid Fundamentals and 2 Facing Headwinds", "content_text": "1 Small-Cap Stock with Solid Fundamentals and 2 Facing Headwinds Many small-cap stocks have limited Wall Street coverage, giving savvy investors the chance to act before everyone else catches on. But the flip side is that these businesses have increased downside risk because they lack the scale and staying power of their larger competitors. Luckily for you, our mission at StockStory is to help you make money and avoid losses by sorting the winners from the losers. That said, here is one small-cap stock that could amplify your portfolio's returns and two best left ignored. Two Small-Cap Stocks ", "date_published": "2026-08-13T14:21:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "GDRX"], "_sharemaestro": {"country": "United States", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "GDRX", "name": "Goodrx Holdings\u00a0Inc", "sentiment_url": "https://sharemaestro.com/sentiment/78134086-d01e-488f-b9bd-1f2f022b49f2/"}]}}, {"id": "source:06da2589273dcb2e4cb196d6f0c0af886dd41dd35e0f762b081f783dec2b06dc", "url": "https://m.investing.com/news/earnings/heartflow-earnings-up-next-can-plaque-analysis-sustain-growth-93CH-4858272?ampMode=1", "external_url": "https://m.investing.com/news/earnings/heartflow-earnings-up-next-can-plaque-analysis-sustain-growth-93CH-4858272?ampMode=1", "title": "Heartflow earnings up next: Can Plaque Analysis sustain growth?", "content_text": "Heartflow Inc. is set to report second-quarter earnings, with analysts anticipating a loss of $0.19 per share, though year-over-year losses are narrowing significantly. Investors will be closely watching the adoption rates of its Plaque Analysis, the sustainability of its revenue growth, and its path to profitability, especially after a strong first quarter driven by its core FFRct technology and Plaque Analysis product. The company's valuation and ability to maintain momentum in AI-powered cardiovascular diagnostics will be key focuses.", "date_published": "2026-08-13T13:13:24+00:00", "authors": [{"name": "Investing.com"}], "tags": ["Earnings", "HTFL"], "_sharemaestro": {"country": "United States", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "HTFL", "name": "Heartflow, Inc. Common Stock", "sentiment_url": "https://sharemaestro.com/sentiment/96e61f2a-ac09-4d51-a8bb-a6e6d25a9b2c/"}]}}, {"id": "source:f81a8416235a127e535588cc4d85e6695ea2b85cd62ed7cd9c9a3315857a9d66", "url": "https://finance.yahoo.com/healthcare/articles/adc-therapeutics-sa-adct-reports-125002536.html", "external_url": "https://finance.yahoo.com/healthcare/articles/adc-therapeutics-sa-adct-reports-125002536.html", "title": "ADC Therapeutics SA (ADCT) Reports Q2 Loss, Lags Revenue Estimates", "content_text": "ADC Therapeutics SA (ADCT) came out with a quarterly loss of $0.11 per share versus the Zacks Consensus Estimate of a loss of $0.19. This compares to a loss of $0.5 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of +42.11%. A quarter ago, it was expected that this company would post a loss of $0.19 per share when it actually produced a loss of $0.21, delivering a surprise of -10.53%. Over the last four quarters, the company has surpassed consensus EPS estimates three times. ADC Therapeutics, which belongs to the Z", "date_published": "2026-08-13T12:50:02+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "PHR"], "_sharemaestro": {"country": "United States", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "PHR", "name": "Phreesia Inc", "sentiment_url": "https://sharemaestro.com/sentiment/f867fd87-bb9f-4dac-b507-192bc95bb558/"}]}}, {"id": "source:53f40eb0183ab4ac381dc42e53f0c95c6e02c2bfca22e0e4a52bf13451e71d1a", "url": "https://www.tradingview.com/news/zacks:721ea0af7094b:0-omnicell-raises-2026-eps-outlook-as-memory-costs-pressure-margins", "external_url": "https://www.tradingview.com/news/zacks:721ea0af7094b:0-omnicell-raises-2026-eps-outlook-as-memory-costs-pressure-margins", "title": "Omnicell Raises 2026 EPS Outlook as Memory Costs Pressure Margins", "content_text": "Omnicell (OMCL) has raised its 2026 earnings outlook after a strong second quarter, though a significant portion of the profit improvement came from a one-time tariff refund. The company faces increased memory-chip costs expected to impact gross margins but plans to leverage cost control and operating efficiency to absorb these pressures. Omnicell's updated guidance also includes widened product bookings and a reduction in annual recurring revenue expectations due to slower development of certain opportunities and lengthy hospital approval cycles.", "date_published": "2026-08-13T12:42:35+00:00", "authors": [{"name": "TradingView"}], "tags": ["Earnings", "OMCL"], "_sharemaestro": {"country": "United States", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "OMCL", "name": "Omnicell Inc", "sentiment_url": "https://sharemaestro.com/sentiment/f64d3a74-c254-46cd-9c7f-e8e836618171/"}]}}, {"id": "source:f5be95e3a06a4e4698cd7f48a1f1fa1cb3e912f9ee36f81c379bc28893acf2fc", "url": "https://www.theglobeandmail.com/investing/markets/markets-news/motley/3825507/privia-health-prva-q2-2026-earnings-call-transcript", "external_url": "https://www.theglobeandmail.com/investing/markets/markets-news/motley/3825507/privia-health-prva-q2-2026-earnings-call-transcript", "title": "Privia Health (PRVA) Q2 2026 Earnings Call Transcript", "content_text": "Privia Health (PRVA) reported strong Q2 2026 results, with net income up 236.7% and total revenue increasing 21.4% year-over-year. The company expanded into New Jersey, now operating in 25 states, and highlighted the successful integration of recent acquisitions and the deployment of AI applications to enhance efficiency and drive long-term margin expansion. Management raised its full-year 2026 guidance across key financial metrics, expressing confidence in its primary care-centric model and ability to capitalize on value-based care programs despite potential delays in CMS shared savings settlements.", "date_published": "2026-08-13T11:11:06+00:00", "authors": [{"name": "The Globe and Mail"}], "tags": ["Earnings", "PRVA"], "_sharemaestro": {"country": "United States", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "PRVA", "name": "Privia Health Group Inc", "sentiment_url": "https://sharemaestro.com/sentiment/604c2b29-650d-4f2d-9955-bca5ec7509ed/"}]}}, {"id": "source:fc7b7a1f95aa9fa9e2cfa2b2048a2950180275b370e730b1666d3271bee6abaa", "url": "https://uk.investing.com/news/stock-market-news/truist-cuts-waystar-stock-price-target-to-33-on-valuation-roll-93CH-4829641", "external_url": "https://uk.investing.com/news/stock-market-news/truist-cuts-waystar-stock-price-target-to-33-on-valuation-roll-93CH-4829641", "title": "Truist cuts Waystar stock price target to $33 on valuation roll", "content_text": "Truist Securities has lowered its price target for Waystar Holding (NASDAQ:WAY) to $33 from $38, while maintaining a Buy rating. This adjustment follows Waystar's Q2 2026 results, with Truist updating its revenue and adjusted EBITDA projections upwards for 2026 and 2027. Despite the price target cut, Truist reiterates confidence in Waystar's growth algorithm, aligning with positive analyst sentiment.", "date_published": "2026-08-13T10:53:37+00:00", "authors": [{"name": "Investing.com UK"}], "tags": ["Analyst action", "WAY"], "_sharemaestro": {"country": "United States", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "WAY", "name": "Waystar Holding Corp. Common Stock", "sentiment_url": "https://sharemaestro.com/sentiment/e19b284a-7576-4888-9963-a3cde3594442/"}]}}, {"id": "source:f3be154ea56d535d963bf62c8a1de82a49ae16283cdcbccee4d669a808cf3355", "url": "https://www.marketscreener.com/news/truist-adjusts-price-target-on-waystar-holding-to-33-from-38-maintains-buy-rating-ce7859d9dc88fe27", "external_url": "https://www.marketscreener.com/news/truist-adjusts-price-target-on-waystar-holding-to-33-from-38-maintains-buy-rating-ce7859d9dc88fe27", "title": "Truist Adjusts Price Target on Waystar Holding to $33 From $38, Maintains Buy Rating", "content_text": "Truist has lowered its price target for Waystar Holding (WAY) to $33 from $38, while reaffirming its \"Buy\" rating on the stock. This adjustment comes amidst other analyst revisions, with Waystar Holding also reporting its Q2 2026 earnings, revenue increases, and revised 2026 outlook.", "date_published": "2026-08-13T10:45:37+00:00", "authors": [{"name": "marketscreener.com"}], "tags": ["Analyst action", "WAY"], "_sharemaestro": {"country": "United States", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "WAY", "name": "Waystar Holding Corp. Common Stock", "sentiment_url": "https://sharemaestro.com/sentiment/e19b284a-7576-4888-9963-a3cde3594442/"}]}}, {"id": "source:c7f6990a2d0c3da839bc661d41390f929f7c33be9209da169d2d9abc37f1c527", "url": "https://www.streetwisereports.com/article/2026/08/12/ai-chronic-care-platform-adds-fifth-fortune-50-client-lifts-margin-to-62.html", "external_url": "https://www.streetwisereports.com/article/2026/08/12/ai-chronic-care-platform-adds-fifth-fortune-50-client-lifts-margin-to-62.html", "title": "AI Chronic Care Platform Adds Fifth Fortune 50 Client, Lifts Margin to 62%", "content_text": "DarioHealth Corp. (DRIO:NASDAQ) reported strong Q2 2026 results, with revenue reaching $5.2 million and gross margin increasing to 62%. The AI-powered chronic care platform secured its fifth Fortune 50 client and expanded into provider-backed care, contributing to a contracted annual recurring revenue (ARR) of $13.1 million, predominantly from multi-condition deals. Analyst Ashok Kumar of ThinkEquity reiterated a Buy rating, raising the price target to $12, citing commercial growth, efficient operations, and margin expansion.", "date_published": "2026-08-13T10:41:37+00:00", "authors": [{"name": "Streetwise Reports"}], "tags": ["Earnings", "DRIO"], "_sharemaestro": {"country": "United States", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "DRIO", "name": "DarioHealth Corp", "sentiment_url": "https://sharemaestro.com/sentiment/358ed596-e9fe-44d3-81df-bdb56fe54d16/"}]}}, {"id": "source:d6833de7415cd19b577350d9e80ba645362d8a5d2f3659bc77f00554ddc28adc", "url": "https://www.marketbeat.com/instant-alerts/filing-royal-bank-of-canada-trims-holdings-in-certara-inc-cert-2026-08-13", "external_url": "https://www.marketbeat.com/instant-alerts/filing-royal-bank-of-canada-trims-holdings-in-certara-inc-cert-2026-08-13", "title": "Royal Bank of Canada Trims Holdings in Certara, Inc. $CERT", "content_text": "Royal Bank of Canada reduced its stake in Certara, Inc. by 19.5% in the first quarter, selling 245,200 shares and retaining over 1 million shares. This comes as Certara reported disappointing quarterly results, missing EPS and revenue expectations, with a 10.8% year-over-year revenue decline and a negative net margin. Despite mixed analyst sentiment leaning towards a \"Hold\" rating with an average price target of $8.28, institutional investors collectively own a significant 73.96% of the company.", "date_published": "2026-08-13T08:41:34+00:00", "authors": [{"name": "MarketBeat"}], "tags": ["Earnings", "CERT"], "_sharemaestro": {"country": "United States", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "CERT", "name": "Certara Inc", "sentiment_url": "https://sharemaestro.com/sentiment/30b13b0c-b5db-41ae-aff1-431d72dbed7e/"}]}}, {"id": "source:b360248497a2355c089386db1dda07584755bcb5d6822642ed8ad3d847e3f976", "url": "https://news.google.com/rss/articles/CBMizwFBVV95cUxQZFVOSlZaaUIxUTd3ZEZaOVZ5TTlma2Y3eDU5dDRYQUxadzRLd1h6OVIwTngxQkVqN3BwV1h4c2lfT3hnWVZoM05IazJZbDdDQmE2NDlncnVsVGRkYy1YYkRhd0JOMy1ILVpmeTl5cE1nTGNUYUVLVTJDblFpZDVVNWZXcFlORDBIdW9kQ21MQ1A4VFpVLU1vWi1UVDVYemUta0xjRFlaR04wUF9kaWpiWHZ5ZTlhVUlLbHhYeU81bllmcXhKaGhLcm9kc3ktQW8?oc=5", "external_url": "https://news.google.com/rss/articles/CBMizwFBVV95cUxQZFVOSlZaaUIxUTd3ZEZaOVZ5TTlma2Y3eDU5dDRYQUxadzRLd1h6OVIwTngxQkVqN3BwV1h4c2lfT3hnWVZoM05IazJZbDdDQmE2NDlncnVsVGRkYy1YYkRhd0JOMy1ILVpmeTl5cE1nTGNUYUVLVTJDblFpZDVVNWZXcFlORDBIdW9kQ21MQ1A4VFpVLU1vWi1UVDVYemUta0xjRFlaR04wUF9kaWpiWHZ5ZTlhVUlLbHhYeU81bllmcXhKaGhLcm9kc3ktQW8?oc=5", "title": "The 5 Most Interesting Analyst Questions From Doximity\u2019s Q2 Earnings Call", "content_text": "The 5 Most Interesting Analyst Questions From Doximity\u2019s Q2 Earnings Call", "date_published": "2026-08-13T08:36:28+00:00", "authors": [{"name": "StockStory"}], "tags": ["Earnings", "DOCS"], "_sharemaestro": {"country": "United States", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "DOCS", "name": "Doximity Inc", "sentiment_url": "https://sharemaestro.com/sentiment/c6ba857b-6a36-47f4-8ae1-3678efe8d188/"}]}}, {"id": "source:1df7d2f241c47f9665798ea5d4bb220ced11004d2d860c9c30c7a0f96bfc800b", "url": "https://stockstory.org/us/stocks/nasdaq/prva/news/earnings-call/the-top-5-analyst-questions-from-privia-healths-q2-earnings-call", "external_url": "https://stockstory.org/us/stocks/nasdaq/prva/news/earnings-call/the-top-5-analyst-questions-from-privia-healths-q2-earnings-call", "title": "The Top 5 Analyst Questions From Privia Health\u2019s Q2 Earnings Call", "content_text": "Privia Health's Q2 results showed strong revenue growth but missed non-GAAP profit expectations, leading to a negative market reaction. Management attributed revenue growth to robust provider signings and expanded value-based attributed lives. This article highlights the top five analyst questions from the earnings call, covering topics like CMS shared savings payments, EBITDA margin confidence, practice collections growth, AI use cases, and acquisition integration.", "date_published": "2026-08-13T08:11:06+00:00", "authors": [{"name": "StockStory"}], "tags": ["Earnings", "PRVA"], "_sharemaestro": {"country": "United States", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "PRVA", "name": "Privia Health Group Inc", "sentiment_url": "https://sharemaestro.com/sentiment/604c2b29-650d-4f2d-9955-bca5ec7509ed/"}]}}, {"id": "source:7ed7ea0ebda65a540c35df38ce994987cab9d00920bbbda160e21da61a16ec17", "url": "https://www.marketbeat.com/instant-alerts/filing-phreesia-inc-phr-stake-lessened-by-dimensional-fund-advisors-lp-2026-08-13", "external_url": "https://www.marketbeat.com/instant-alerts/filing-phreesia-inc-phr-stake-lessened-by-dimensional-fund-advisors-lp-2026-08-13", "title": "Phreesia, Inc. $PHR Stake Lessened by Dimensional Fund Advisors LP", "content_text": "Dimensional Fund Advisors LP reduced its stake in Phreesia, Inc. (NYSE:PHR) by 22.9% in the first quarter, selling 143,563 shares and retaining 484,717 shares valued at $4.07 million. Despite this reduction, institutional investors collectively own 92.1% of the company. Phreesia reported strong Q1 earnings with EPS of $0.05, beating estimates, and a 12.9% year-over-year revenue increase to $130.94 million, while analysts currently rate the stock as a \"Hold\" with an average price target of $16.65.", "date_published": "2026-08-13T08:10:07+00:00", "authors": [{"name": "MarketBeat"}], "tags": ["Earnings", "PHR"], "_sharemaestro": {"country": "United States", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "PHR", "name": "Phreesia Inc", "sentiment_url": "https://sharemaestro.com/sentiment/f867fd87-bb9f-4dac-b507-192bc95bb558/"}]}}, {"id": "source:6e5e496fee9e8f7dd660bc55c14e9622dcf87b634b360743a64b7b4541ad98c4", "url": "https://news.google.com/rss/articles/CBMioAFBVV95cUxOWXJVbEdBWFNJdVlSX2taTlYwMHN6S3lsT29rTFZQOWNhNkhSQWZUUnNqbGtKdW16NkNUckNuWmlEU0JKdE5peG54WUQ3MGdoTzhDZWdPcm94blRxUl81MzRMM08yNWtmTDVBZDRGSGhqcVZFMkZXWWxBU21ISGxfYUVqLXVYak1jdVdUd3k0Z1p1Y09TZEthNW1GZGQxdHFS?oc=5", "external_url": "https://news.google.com/rss/articles/CBMioAFBVV95cUxOWXJVbEdBWFNJdVlSX2taTlYwMHN6S3lsT29rTFZQOWNhNkhSQWZUUnNqbGtKdW16NkNUckNuWmlEU0JKdE5peG54WUQ3MGdoTzhDZWdPcm94blRxUl81MzRMM08yNWtmTDVBZDRGSGhqcVZFMkZXWWxBU21ISGxfYUVqLXVYak1jdVdUd3k0Z1p1Y09TZEthNW1GZGQxdHFS?oc=5", "title": "GoodRx (GDRX) Stock Looks Overvalued On Its Earnings Outlook", "content_text": "GoodRx (GDRX) Stock Looks Overvalued On Its Earnings Outlook", "date_published": "2026-08-13T08:09:34+00:00", "authors": [{"name": "Market source"}], "tags": ["Earnings", "GDRX"], "_sharemaestro": {"country": "United States", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "GDRX", "name": "Goodrx Holdings\u00a0Inc", "sentiment_url": "https://sharemaestro.com/sentiment/78134086-d01e-488f-b9bd-1f2f022b49f2/"}]}}, {"id": "source:bc71a27e158c0f811980d996bffe602a13fc6f5280b214dddb6e2226d1ff352e", "url": "https://news.google.com/rss/articles/CBMimgFBVV95cUxORi1ZU2M2T3B1UHA5OU84ZlQwTFFnOEo5ZmlmVlgyTGhfSGVsNlAwUm8xT2FmXzFlY1V1WXZrZ0lmLWVFZGZyTEVna0lGcDMtOHdDdThPX0d2dHBTTUJOR0RTaWV3aXZ3OVd0MzdNOWhkbGJXNTdBMnRKSG9jRGFPWTZiRERJOUlXWmI4bEphRVkzcHdRWVdLQ1N3?oc=5", "external_url": "https://news.google.com/rss/articles/CBMimgFBVV95cUxORi1ZU2M2T3B1UHA5OU84ZlQwTFFnOEo5ZmlmVlgyTGhfSGVsNlAwUm8xT2FmXzFlY1V1WXZrZ0lmLWVFZGZyTEVna0lGcDMtOHdDdThPX0d2dHBTTUJOR0RTaWV3aXZ3OVd0MzdNOWhkbGJXNTdBMnRKSG9jRGFPWTZiRERJOUlXWmI4bEphRVkzcHdRWVdLQ1N3?oc=5", "title": "GoodRx Holdings (GDRX) Could Be 13% Overvalued After Q2 Earnings and Guidance Raise", "content_text": "GoodRx Holdings (GDRX) Could Be 13% Overvalued After Q2 Earnings and Guidance Raise", "date_published": "2026-08-13T07:51:42+00:00", "authors": [{"name": "Market source"}], "tags": ["Earnings", "GDRX"], "_sharemaestro": {"country": "United States", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "GDRX", "name": "Goodrx Holdings\u00a0Inc", "sentiment_url": "https://sharemaestro.com/sentiment/78134086-d01e-488f-b9bd-1f2f022b49f2/"}]}}, {"id": "source:71d5e5972f935a1f3fbb093dcc16830cdb49b1b19482599b437d754080c60e42", "url": "https://www.moomoo.com/news/post/74600401/stifel-maintains-weave-communications-weavus-with-buy-rating-maintains-target", "external_url": "https://www.moomoo.com/news/post/74600401/stifel-maintains-weave-communications-weavus-with-buy-rating-maintains-target", "title": "Stifel Maintains Weave Communications(WEAV.US) With Buy Rating, Maintains Target Price $8", "content_text": "Stifel has reiterated its Buy rating on Weave Communications (WEAV.US) and maintained its target price of $8. This indicates the firm's continued confidence in the company's performance and future prospects at the current valuation.", "date_published": "2026-08-13T05:10:33+00:00", "authors": [{"name": "Moomoo"}], "tags": ["Analyst action", "WEAV"], "_sharemaestro": {"country": "United States", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "WEAV", "name": "Weave Communications Inc", "sentiment_url": "https://sharemaestro.com/sentiment/a1875753-66a3-44cb-850f-453d93fb31e7/"}]}}, {"id": "source:ca8e02c75a39a49d50feefce028daea4d4e80f9ef1c1d8047ea9345242e4726b", "url": "https://m.investing.com/news/insider-trading-news/heartflow-ceo-john-farquhar-sells-638730-in-common-stock-93CH-4856284?ampMode=1", "external_url": "https://m.investing.com/news/insider-trading-news/heartflow-ceo-john-farquhar-sells-638730-in-common-stock-93CH-4856284?ampMode=1", "title": "Heartflow CEO John Farquhar sells $638,730 in common stock", "content_text": "Heartflow CEO John C.M. Farquhar sold 22,562 shares of the company's common stock for approximately $638,730. This transaction was executed under a Rule 10b5-1 trading plan. The company recently reported strong Q1 2026 earnings, exceeding analyst expectations, and has received positive ratings from several financial firms.", "date_published": "2026-08-13T02:40:58+00:00", "authors": [{"name": "Investing.com"}], "tags": ["Earnings", "HTFL"], "_sharemaestro": {"country": "United States", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "HTFL", "name": "Heartflow, Inc. Common Stock", "sentiment_url": "https://sharemaestro.com/sentiment/96e61f2a-ac09-4d51-a8bb-a6e6d25a9b2c/"}]}}, {"id": "source:916e1a04d1dbf454e6456b1770d04b8f7058f42d695b227fac0a15611fb02155", "url": "https://sg.finance.yahoo.com/research/reports/ARGUS_6745_QuantitativeReport_1786492800000", "external_url": "https://sg.finance.yahoo.com/research/reports/ARGUS_6745_QuantitativeReport_1786492800000", "title": "Waystar Holding Corp. (WAY) Stock forecasts", "content_text": "This article provides a stock forecast for Waystar Holding Corp. (WAY), identifying it as a provider of mission-critical cloud technology to healthcare organizations. It highlights a report from Argus dated August 12, 2026, which includes a current price of $25.08 and a price target for the stock, with an option to download the full report. The article also mentions related reports for other companies with updated target prices.", "date_published": "2026-08-13T02:09:59+00:00", "authors": [{"name": "Market source"}], "tags": ["Guidance", "WAY"], "_sharemaestro": {"country": "United States", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "WAY", "name": "Waystar Holding Corp. Common Stock", "sentiment_url": "https://sharemaestro.com/sentiment/e19b284a-7576-4888-9963-a3cde3594442/"}]}}, {"id": "source:4e5bfb5362058afbb813bc5f55c4457093dc041b622995a235d862b11cc25f2a", "url": "https://www.stocktitan.net/sec-filings/HNGE/form-4-hinge-health-inc-insider-trading-activity-8e5f38ae6d0f.html", "external_url": "https://www.stocktitan.net/sec-filings/HNGE/form-4-hinge-health-inc-insider-trading-activity-8e5f38ae6d0f.html", "title": "Hinge Health (HNGE) director gains indirect ownership of 4,637 Class A shares", "content_text": "Hinge Health, Inc. director Teddie Benjamin Wardi indirectly acquired 4,637 shares of Class A Common Stock. These shares were received by Ingentorsk (Delaware) LLC through distributions from Insight Venture Associates X, L.P. and Insight Venture Partners X (Class A), L.P., with no monetary consideration paid. Wardi controls Ingentorsk and is considered a beneficial owner of these securities.", "date_published": "2026-08-13T01:41:05+00:00", "authors": [{"name": "Stock Titan"}], "tags": ["Market update", "HNGE"], "_sharemaestro": {"country": "United States", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "HNGE", "name": "Hinge Health, Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/5e193ce6-020e-42a6-9585-2f3b4a202c69/"}]}}, {"id": "source:00cc3bd664c073eafeb934bf04163c98fea361acfa7bf3836b66417439034cc3", "url": "https://www.marketbeat.com/instant-alerts/heartflow-nasdaqhtfl-ceo-john-cm-farquhar-sells-22562-shares-2026-08-12", "external_url": "https://www.marketbeat.com/instant-alerts/heartflow-nasdaqhtfl-ceo-john-cm-farquhar-sells-22562-shares-2026-08-12", "title": "Heartflow (NASDAQ:HTFL) CEO John C.M. Farquhar Sells 22,562 Shares", "content_text": "Heartflow CEO John C.M. Farquhar sold 22,562 shares of the company's stock for over $638,000, reducing his direct holdings by 4.92%. This transaction was made under a pre-arranged Rule 10b5-1 trading plan. Despite the insider sale, Heartflow's stock rose 1.0%, and the company exceeded Q1 earnings per share estimates with a 41.3% increase in revenue year-over-year, leading to a \"Moderate Buy\" consensus among analysts.", "date_published": "2026-08-12T23:40:58+00:00", "authors": [{"name": "MarketBeat"}], "tags": ["Earnings", "HTFL"], "_sharemaestro": {"country": "United States", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "HTFL", "name": "Heartflow, Inc. Common Stock", "sentiment_url": "https://sharemaestro.com/sentiment/96e61f2a-ac09-4d51-a8bb-a6e6d25a9b2c/"}]}}, {"id": "source:c23b471ac10409ed056fc79b35765e70ddd4db5a39805f71192d2161ac96f290", "url": "https://www.marketbeat.com/instant-alerts/omada-health-nasdaqomda-president-sells-8866-shares-2026-08-12", "external_url": "https://www.marketbeat.com/instant-alerts/omada-health-nasdaqomda-president-sells-8866-shares-2026-08-12", "title": "Omada Health (NASDAQ:OMDA) President Sells 8,866 Shares", "content_text": "Omada Health's President, Wei-Li Shao, sold 8,866 shares of OMDA stock for $221,827, reducing his direct stake by 2.8%. This sale occurred after Omada Health reported a strong second quarter, with EPS of $0.08 and revenue of $87.83 million, exceeding analyst expectations. Despite positive earnings and a \"Moderate Buy\" consensus from analysts, the stock trades at a high price-to-earnings ratio near 477.", "date_published": "2026-08-12T22:40:25+00:00", "authors": [{"name": "MarketBeat"}], "tags": ["Earnings", "OMDA"], "_sharemaestro": {"country": "United States", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "OMDA", "name": "Omada Health, Inc. Common Stock", "sentiment_url": "https://sharemaestro.com/sentiment/a321a462-e615-4e2f-95f8-a1506dcf93ae/"}]}}, {"id": "source:a73013618327d6c2f4d4dece2931bf1a4810c08bcfc9ffb93ab147b50a47ed50", "url": "https://ca.investing.com/news/stock-market-news/omada-health-president-weili-shao-sells-221798-in-stock-93CH-4796618", "external_url": "https://ca.investing.com/news/stock-market-news/omada-health-president-weili-shao-sells-221798-in-stock-93CH-4796618", "title": "Omada Health president Wei-Li Shao sells $221,798 in stock By Investing.com", "content_text": "Wei-Li Shao, President of Omada Health Inc. (NASDAQ:OMDA), sold 8,866 shares of the company's common stock for $221,798 on August 12, 2026, executed via a 10b5-1 trading plan. This sale occurred after the stock surged 114% over six months, with InvestingPro analysis suggesting it is overvalued. Despite this insider sale, Omada Health recently reported strong Q2 results, including a 43% revenue increase, positive adjusted EPS and EBITDA, leading BTIG to raise its price target to $35 with a Buy rating.", "date_published": "2026-08-12T22:40:25+00:00", "authors": [{"name": "Investing.com Canada"}], "tags": ["Earnings", "OMDA"], "_sharemaestro": {"country": "United States", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "OMDA", "name": "Omada Health, Inc. Common Stock", "sentiment_url": "https://sharemaestro.com/sentiment/a321a462-e615-4e2f-95f8-a1506dcf93ae/"}]}}, {"id": "source:5d7859146edffa3b45b3a9b01b357fed58d488eb45767133045b49bf01a538f3", "url": "https://finance.yahoo.com/markets/stocks/articles/veeva-systems-veev-exceeds-market-214503951.html", "external_url": "https://finance.yahoo.com/markets/stocks/articles/veeva-systems-veev-exceeds-market-214503951.html", "title": "Veeva Systems (VEEV) Exceeds Market Returns: Some Facts to Consider", "content_text": "Veeva Systems (VEEV) closed at $241.51 in the latest trading session, marking a +2.08% move from the prior day. The stock exceeded the S&P 500, which registered a gain of 0.26% for the day. On the other hand, the Dow registered a loss of 0.04%, and the technology-centric Nasdaq increased by 0.54%. The stock of provider of cloud-based software services for the life sciences industry has risen by 22.52% in the past month, leading the Medical sector's gain of 2.89% and the S&P 500's gain of 2.13%. The upcoming earnings release of Veeva Systems will be of great interest to investors. The company's", "date_published": "2026-08-12T21:45:03+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "VEEV"], "_sharemaestro": {"country": "United States", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "VEEV", "name": "Veeva Systems Inc Class A", "sentiment_url": "https://sharemaestro.com/sentiment/60f17108-f228-452e-9be1-7f86c73f1769/"}]}}, {"id": "source:311fd7944e01ed3890ab649d61b316c145f1362350b968bcdb8f09b9fe7ae6d3", "url": "https://m.investing.com/news/insider-trading-news/omada-health-cfo-steven-cook-sells-421k-in-stock-93CH-4856230?ampMode=1", "external_url": "https://m.investing.com/news/insider-trading-news/omada-health-cfo-steven-cook-sells-421k-in-stock-93CH-4856230?ampMode=1", "title": "Omada Health CFO Steven Cook sells $421k in stock", "content_text": "Omada Health CFO Steven Cook sold approximately $421,547 worth of company stock and acquired shares totaling $138,754 through option exercises. These transactions occurred on August 10 and 11, 2026, under a pre-arranged trading plan, following a significant 114% surge in OMDA shares. The company also recently reported strong Q2 financial results, exceeding revenue and earnings expectations, leading to a raised price target from BTIG.", "date_published": "2026-08-12T21:40:25+00:00", "authors": [{"name": "Investing.com"}], "tags": ["Earnings", "OMDA"], "_sharemaestro": {"country": "United States", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "OMDA", "name": "Omada Health, Inc. Common Stock", "sentiment_url": "https://sharemaestro.com/sentiment/a321a462-e615-4e2f-95f8-a1506dcf93ae/"}]}}, {"id": "source:cdb76f4589c901ed3ec206c3dc58ae1aa23020b47610ef0f47500102fd7598ce", "url": "https://finance.yahoo.com/markets/stocks/articles/optimizerx-corp-oprx-q2-earnings-214004727.html", "external_url": "https://finance.yahoo.com/markets/stocks/articles/optimizerx-corp-oprx-q2-earnings-214004727.html", "title": "OptimizeRx Corp. (OPRX) Q2 Earnings and Revenues Top Estimates", "content_text": "OptimizeRx Corp. (OPRX) came out with quarterly earnings of $0.16 per share, beating the Zacks Consensus Estimate of $0.11 per share. This compares to earnings of $0.24 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of +45.46%. A quarter ago, it was expected that this company would post earnings of $0.01 per share when it actually produced earnings of $0.14, delivering a surprise of +1300%. Over the last four quarters, the company has surpassed consensus EPS estimates four times. OptimizeRx, which belongs to the Zacks Computer - Software industry, posted revenues of $20.5 million for the quarter ended June 2026, surpassing the Zacks Consensus Estimate by 0.11%. This compares to year-ago revenues of $29.19 million. The company has topped consensus revenue estimates four times over the last four quarters. The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call. OptimizeRx shares have lost about 43.6% since the beginning of the year versus the S&P 500's gain of 12.9%. What's Next for OptimizeRx? While OptimizeRx has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock? There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately. Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions. Ahead of this earnings release, the estimate revisions trend for OptimizeRx was mixed. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. It will be interesting to see how estimates for the coming quarters and the current fiscal year change in the days ahead. The current consensus EPS estimate is $0.24 on $25.92 million in revenues for the coming quarter and $0.91 on $97.89 million in revenues for the current fiscal year. Story Continues Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Computer - Software is currently in the top 29% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1. Synopsys (SNPS), another stock in the same industry, has yet to report results for the quarter ended July 2026. The results are expected to be released on August 26. This maker of software used to test and develop chips is expected to post quarterly earnings of $3.68 per share in its upcoming report, which represents a year-over-year change of +8.6%. The consensus EPS estimate for the quarter has remained unchanged over the last 30 days. Synopsys' revenues are expected to be $2.44 billion, up 40.3% from the year-ago quarter. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report OptimizeRx Corp. (OPRX) : Free Stock Analysis Report Synopsys, Inc. (SNPS) : Free Stock Analysis Report This article originally published on Zacks Investment Research (zacks.com). Zacks", "date_published": "2026-08-12T21:40:04+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Market update", "OPRX"], "_sharemaestro": {"country": "United States", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "OPRX", "name": "OPTIMIZERx Corp", "sentiment_url": "https://sharemaestro.com/sentiment/122f93db-84ce-4726-9104-b2a4f819cb44/"}]}}, {"id": "source:fa2e8719495039ceb63bf08d06d7f5a89c2998a57ae67b7bcdcd3e623bddae15", "url": "https://www.stocktitan.net/sec-filings/OMDA/144-omada-health-inc-sec-filing-d34908842126.html", "external_url": "https://www.stocktitan.net/sec-filings/OMDA/144-omada-health-inc-sec-filing-d34908842126.html", "title": "OMDA (OMDA) insider plans Rule 144 sale as 8,866 shares valued at $212,872", "content_text": "An insider at Omada Health, Inc. (OMDA) plans a Rule 144 sale of 8,866 common shares, valued at approximately $212,872.66, through Morgan Stanley Smith Barney LLC Executive Financial Services. These shares, acquired from restricted stock units on June 1, 2026, are slated for sale on or after August 12, 2026, on NASDAQ. The filing also notes a previous Rule 10b5-1 sale by Wei-Li Shao of 4,037 shares for $69,600.71 within the last three months.", "date_published": "2026-08-12T20:40:25+00:00", "authors": [{"name": "Stock Titan"}], "tags": ["Market update", "OMDA"], "_sharemaestro": {"country": "United States", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "OMDA", "name": "Omada Health, Inc. Common Stock", "sentiment_url": "https://sharemaestro.com/sentiment/a321a462-e615-4e2f-95f8-a1506dcf93ae/"}]}}, {"id": "source:6f05e9049a049dc76faa7e3725389471f53d48f70238c34f1496559ca37b4453", "url": "https://www.tradingview.com/news/tradingview:47c901c4c8d36:0-talkspace-merger-closing-expected-around-aug-17-after-state-healthcare-clearances", "external_url": "https://www.tradingview.com/news/tradingview:47c901c4c8d36:0-talkspace-merger-closing-expected-around-aug-17-after-state-healthcare-clearances", "title": "Talkspace merger closing expected around Aug. 17 after state healthcare clearances", "content_text": "Talkspace (TALK) announced that all state healthcare waiting periods and approvals for its merger with Universal Health Services have been cleared as of August 11, 2026. The merger will make Talkspace an indirect wholly-owned subsidiary of Universal Health Services, with closing anticipated around August 17, 2026, pending remaining conditions. The company cautioned that the closing is subject to other conditions and forward-looking risks.", "date_published": "2026-08-12T20:14:19+00:00", "authors": [{"name": "TradingView"}], "tags": ["Deals and strategy", "TALK"], "_sharemaestro": {"country": "United States", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "TALK", "name": "Talkspace Inc", "sentiment_url": "https://sharemaestro.com/sentiment/a07815f3-ff75-4e35-a069-afbf8f725c96/"}]}}, {"id": "source:30c97f336ab2aca11716683f5ba05bbe6c227ce87e1b785bbabfe87eb57a2545", "url": "https://finance.yahoo.com/markets/stocks/articles/resideo-appoints-shane-harrison-chief-200600256.html", "external_url": "https://finance.yahoo.com/markets/stocks/articles/resideo-appoints-shane-harrison-chief-200600256.html", "title": "Resideo Appoints Shane Harrison as Chief Financial Officer", "content_text": "SCOTTSDALE, Ariz., Aug. 12, 2026 /PRNewswire/ -- Resideo Technologies (NYSE: REZI) (\"Resideo\"), a leading global developer and manufacturer of critical control and sensing solutions for residential end markets, today announced that Shane Harrison has been appointed as Resideo's Chief Financial Officer, effective September 1, 2026. Mr. Harrison is a seasoned finance leader with more than 25 years of experience across corporate finance, investor relations, and strategic transactions. He joins Resideo from NRC Health, a publicly traded healthcare technology and analytics company, where he served as Chief Financial Officer and was previously Senior Vice President of Finance and Investor Relations at PowerSchool, a leading K-12 education software provider. He has also served as Senior Vice President of Corporate Development at NAVEX Global, a risk and compliance-based software business, and held several senior leadership roles at FLIR Systems, a provider of perception and awareness technologies, including Senior Vice President of Corporate Development and Investor Relations, Corporate Treasurer and Interim Chief Financial Officer. He began his career at Deloitte and was an investment banker at Lehman Brothers. He holds a B.S. in Accounting from the University of Oregon and an MBA from the UCLA Anderson School of Management. Tom Surran, President and Chief Executive Officer of Resideo, said, \"I am excited to welcome Shane as our CFO and leverage his decades of finance leadership to achieve our near- and longer-term financial goals. I look forward to partnering with Shane to drive growth, expand margins, and generate strong cash flow to create long-term shareholder value.\" \"This is an exciting time to join Resideo as the Company starts this next chapter following the spin-off transaction,\" said Mr. Harrison. \"The Company's leading brands, innovation pipeline, track record of financial performance, and exceptional team are a tremendous foundation for further growth.\" About Resideo Resideo is a global building technologies company that is a leading developer and manufacturer of critical control and sensing solutions for residential markets. The company serves professional installers and integrators across diverse product categories, such as heating, ventilation, and air conditioning controls, combustion, life safety, security, and water. Its comfort and protection solutions can be found in more than 150 million residential and commercial spaces globally, with tens of millions of new devices sold annually. More information about Resideo and its trusted brands, including BRK, First Alert, and Honeywell Home, is available at resideo.com. Story Continues Contacts Investors: Christopher T. Lee Global Head of Strategic Finance investorrelations@resideo.com Media: Kevin Hunt Communications Director kevin.hunt@resideo.com Or Dan Moore, Tali Epstein Collected Strategies Resideo-CS@collectedstrategies.comCision View original content to download multimedia:https://www.prnewswire.com/news-releases/resideo-appoints-shane-harrison-as-chief-financial-officer-302850104.html View Comments", "date_published": "2026-08-12T20:06:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Market update", "NRC"], "_sharemaestro": {"country": "United States", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "NRC", "name": "National Research Corp", "sentiment_url": "https://sharemaestro.com/sentiment/371b407f-7425-4483-9dc0-7f047fc077df/"}]}}, {"id": "source:2d3833645875d5d0f987193bed3d52fdc4967471381f21feb4e78b2b8e1f4d5f", "url": "https://news.google.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?oc=5", "external_url": "https://news.google.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?oc=5", "title": "Hinge Health (HNGE) Stock Could Be Overvalued On Its 95% Run", "content_text": "Hinge Health (HNGE) Stock Could Be Overvalued On Its 95% Run", "date_published": "2026-08-12T19:41:39+00:00", "authors": [{"name": "simplywall.st"}], "tags": ["Market update", "HNGE"], "_sharemaestro": {"country": "United States", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "HNGE", "name": "Hinge Health, Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/5e193ce6-020e-42a6-9585-2f3b4a202c69/"}]}}, {"id": "source:7835a6b4b376fa6f740670085bc029bc18c05ead14857e55d06d331eda00396f", "url": "https://finance.yahoo.com/markets/stocks/articles/dxcm-stock-worth-buying-growth-183600592.html", "external_url": "https://finance.yahoo.com/markets/stocks/articles/dxcm-stock-worth-buying-growth-183600592.html", "title": "Is DXCM Stock Worth Buying as Growth Improves but Valuation Stretches?", "content_text": "DexCom, Inc. DXCM is entering the second half of 2026 with healthier margins, broader reimbursement and a larger continuous glucose monitoring opportunity. The investment question is whether that improving setup is enough to justify a premium valuation. Growth catalysts remain visible across U.S. coverage, product upgrades and international expansion. Yet competition, litigation and a forward earnings multiple above key benchmarks leave less room for execution misses. DXCM's Growth Case Is Still Broadening DexCom's addressable market is widening beyond intensive insulin users. All four of the ", "date_published": "2026-08-12T18:36:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "MMED"], "_sharemaestro": {"country": "United States", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "MMED", "name": "MiniMed Group, Inc. Common Stock", "sentiment_url": "https://sharemaestro.com/sentiment/f9964ac5-b087-4f4b-a1d2-247715caabaf/"}]}}]}